RETA Stock News

U.S. stocks traded higher this morning, following the release of strong jobs data on Friday. The Dow traded up 0.51% to 32,971.92 while the NASDAQ rose 0.79% to 12,758. The S&P also rose, gaining, 0.5

Reata Pharmaceuticals, Inc. (NASDAQ:RETA ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants Warren Huff - Chief Executive Officer Colin Meyer - Chief Innovation Officer

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -6.32% and 70.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -6.32% and 70.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.12% and 6.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Gilead (GILD) delivered earnings and revenue surprises of 4.64% and 6.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announce

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday. Rubicon Technology, Inc. (NASDAQ: RBCN) shares surged 66.1% to settle at $15.05 on Tuesday after the c

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?

Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.

Over the past 3 months, 4 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock. These analysts are typically employed by large Wall Street banks and tasked with understan

Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. The FDA grants priority review to the NDA for the same. Stock rises.

Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. The FDA grants priority review to the NDA for the same.

Shares of Reata Pharmaceuticals Inc. RETA, +3.01% were up 2.4% in trading on Thursday after the company said the Food and Drug Administration granted priority review to the company's experimental trea